Obesity-related albuminuria is associated with decline of kidney function and is considered a first sign of diabetic nephropathy. Suggested factors linking obesity to kidney dysfunction include low-grade inflammation, insulin resistance and adipokine dysregulation. Here, we investigated the effects of two pharmacological compounds with established anti-inflammatory properties, rosiglitazone and rosuvastatin, on kidney dysfunction during high-fat diet (HFD)-induced obesity. For this, human CRP transgenic mice were fed standard chow, a lard-based HFD, HFD+rosuvastatin or HFD+rosiglitazone for 42 weeks to study effects on insulin resistance; plasma inflammatory markers and adipokines; and renal pathology. Rosiglitazone but not rosuvastatin prevented HFD-induced albuminuria and renal fibrosis and inflammation. Also, rosiglitazone prevented HFD-induced KIM-1 expression, while levels were doubled with rosuvastatin. This was mirrored by miR-21 expression, which plays a role in fibrosis and is associated with renal dysfunction. Plasma insulin did not correlate with albuminuria. Only rosiglitazone increased circulating adiponectin concentrations. In all, HFD-induced albuminuria, and renal inflammation, injury and fibrosis is prevented by rosiglitazone but not by rosuvastatin. These beneficial effects of rosiglitazone are linked to lowered miR-21 expression but not connected with the selectively enhanced plasma adiponectin levels observed in rosiglitazone-treated animals.
reduce systemic inflammation and insulin are attractive candidates for preventive treatment of patients at risk for developing (diabetic) nephropathy.
Another explanation for renal disease in obesity may be related to the notion that adipocytes are an active endocrine cell type 8, 9 . Adipocytes secrete several bioactive factors (adipokines) that reportedly play a role in maintaining metabolic health (reviewed in ref. 8) . Obesity frequently leads to a dysregulation of adipokine secretion from fat depots 8 and thus may be associated with metabolic diseases. Of the numerous factors that are regulated with increased visceral obesity, one of the best characterised is adiponectin. Recent clinical studies suggest that lowered plasma levels of adiponectin may play a key role in the development of obesity-related albuminuria 10 . Adiponectin is thought to regulate the function of podocytes, a renal cell-type that plays a significant role in the glomerular filtration barrier 11 . Indeed, studies in adiponectin knockout mice indicate that absence of adiponectin can contribute to the initial development of albuminuria 10 . Further evidence for beneficial effects of adiponectin on kidney functioning was sought by increasing plasma levels by administration of exogenous adiponectin, but these efforts were hampered by inherent difficulties in producing functional recombinant adiponectin, combined with the brief circulating half-life of adiponectin 12 . Therefore, efforts to increase adiponectin levels have also been focused on increasing the production of endogenous adiponectin by adipose tissue. Since the human and mouse adiponectin promoter contains binding sites for peroxisome proliferator-activated receptor gamma (PPAR-γ), pharmacological activation of PPAR-γ offers the opportunity to enhance endogenous plasma levels of adiponectin and thereby to further substantiate a protective role of adiponectin in the development of kidney disease.
To gain more insight into the role of inflammation and adiponectin in metabolic-stress-induced albuminuria, renal inflammation and fibrosis in the context of IR, we used a human CRP transgenic (huCRPtg) mouse model. The huCRPtg mouse carries a transgene containing the human CRP gene, the 5′ flanking promoter region and all known human CRP gene regulatory elements 13 . These mice have been successfully employed to monitor systemic inflammation and to determine the effects and mechanisms of drugs like statins and fibrates in reducing inflammatory process 14 . In a recent study 15 , we demonstrated that by feeding a high-fat diet (HFD), huCRPtg mice showed metabolic-stress-induced systemic inflammation and developed osteoarthritis. Interventions with a statin (rosuvastatin) and a PPAR-γ activator (rosiglitazone) reduced systemic inflammation as indicated by decreased human CRP levels and concomitantly inhibited the development of osteoarthritis. Here we have used this mouse model to evaluate whether suppression of HFD-induced systemic inflammation by rosuvastatin and rosiglitazone also improves albuminuria, renal inflammation and fibrosis under conditions of obesity and IR. An integral part of the study was to assess a putative role of adiponectin, which is induced by rosiglitazone.
Results
Body weight and fat distribution. HuCRPtg mice were fed a standard chow diet, a lard-based HFD, HFD+0.005% rosuvastatin or HFD+0.018% rosiglitazone for 42 weeks to study effects on insulin resistance, plasma inflammatory markers and adipokines, and renal pathology (albuminuria, inflammation and fibrosis). Body weight at baseline (t = 0) was 28.5 ± 2.1 g. The three experimental groups that received HFD all showed a gradual increase in body weight over time and all had significantly higher average body weights at the end of the experimental period (t = 42 weeks) compared with the group that remained on chow (35.1 ± 1.9 g). Mice treated with rosiglitazone had the highest body weight (57.7 ± 11.0 g), which was significantly higher than that of the HFD group (41.1 ± 4.7 g) and the rosuvastatin-treated group (46.1 ± 6.2 g) 15 .
All mice fed HFD showed a clear increase in fat mass compared with chow-fed mice, but what was most striking were the observed differences in fat mass distribution over the various fat depots in the different groups (Fig. 1a-c Glucose and insulin levels. Plasma glucose levels were 9.8 ± 1.21 mM at the start of the experiment and increased steadily and significantly during the rest of the investigational period for all experimental groups: 13.6 ± 1.8 mM (chow), 15.9 ± 2.5 mM (HFD), 14.8 ± 2.1 mM (HFD+Rosuva), and 14.2 ± 2.1 mM (HFD+Rosi) at t = 42 (Fig. 2a) . Compared with glucose levels, changes in insulin levels over time were more pronounced and differed between groups. Average insulin levels were 0.6 ± 0.3 ng/ml at t = 0 and rose over time to 3.4 ± 1.7 ng/ ml at t = 42 weeks for the chow group and to 4.1 ± 0.6 ng/ml in HFD. Notably, the highest insulin levels were observed with rosuvastatin treatment (4.7 ± 1.0 ng/ml), whereas rosiglitazone treatment markedly and significantly suppressed insulin levels to 2.3 ± 1.6 ng/ml (p < 0.05 compared with HFD) (Fig. 2b) .
Plasma adipokines.
Leptin is an adipokine that is highly specific for adipose tissue. Several studies of obese humans have shown a strong and consistent positive relation between plasma leptin concentrations and adipose tissue mass (see ref. 16 and references therein). At the start of the experiment, plasma leptin levels were low (0.15 ± 0.3 ng/ml) and they increased slightly over time in the chow group (4.7 ± 2.2 ng/ml at t = 42 weeks) (Fig. 3a) . After starting the HFD, leptin levels gradually and strongly rose in all three HFD groups ( Fig. 3a) . At t = 42 weeks, leptin levels in the rosiglitazone group had reached values of 35.9 ± 19.5 ng/ml, higher than those of the rosuvastatin group (30.1 ± 11.2 ng/ml) and the HFD group (21.8 ± 10.9 ng/ml, p < 0.05). Correlation analysis revealed a strong positive relationship between body mass and leptin levels (R 2 = 0.8208, p < 0.0001, Fig. 3b ), in line with the reported correlation between plasma leptin levels and adipose mass in humans 16 . In contrast to leptin, adiponectin levels are usually reduced with increasing obesity and associated comorbidities, such as type-2 diabetes (T2D) 17 . Grosso modo, adiponectin levels remained relatively constant in all treatment groups during the entire experimental period (t = 0: 7.4 ± 2.5 µg/ml; and t = 42: 9.4 ± 3.3 µg/ml in chow, 11.9 ± 1.2 µg/ ml in HFD, and 10.9 ± 2.8 µg/ml in HFD+Rosuva), except for the rosiglitazone group, which showed strongly increased plasma concentrations of adiponectin from t = 4 weeks onward, reaching average levels of 40.8 ± 9.9 µg/ ml (p < 0.001 compared with all other groups at t = 42, Fig. 3c ).
Renal inflammation and renal function.
At the end of the experimental period, the chow group had a urinary albumin/creatinine ratio of 151 ± 57 µg/mg. Both the HFD group (396 ± 232 µg/mg, p < 0.01) and the Rosuva group (361 ± 232 µg/mg, p < 0.05) showed a comparable and significant increase in the albumin/ creatinine ratio compared with the chow group (Fig. 4a) . In contrast, HFD-fed mice treated with rosiglitazone exhibited urinary albumin/creatinine ratios of 129 ± 20 µg/mg, i.e. similar to those of chow-fed mice, and well below the values seen for the HFD and Rosuva groups (p < 0.01 compared with HFD, p < 0.05 compared with HFD+Rosuva; Fig. 4a) . Notably, urinary albumin levels were not significantly correlated with plasma insulin levels (not shown).
Bright-field microscopy analysis revealed that HFD feeding induced development of mild mesangial area expansion and accumulation of lipid droplets in tubuli (Fig. 4b) . Both rosuvastatin and rosiglitazone prevented mesangial expansion. Tubular lipid accumulation was also observed in the rosiglitazone-treated group, but was absent in the rosuvastatin-treated mice.
Gene expression analysis revealed that relative mRNA expression levels (expressed as fold-change relative to chow) of kidney injury molecule 1 (KIM-1) were markedly upregulated in HFD (2.15 ± 0.84, p = 0.08 vs. chow, Table 1 ). Notably, rosuvastatin markedly and significantly further increased KIM-1 expression levels (3.56 ± 2.18, p < 0.05 vs. HFD), whereas rosiglitazone kept KIM-1 mRNA levels as low as those found for the chow group, i.e. strikingly below values seen for the HFD and HFD+Rosuva groups. Immunofluorescence staining of KIM-1 A similar pattern emerged with respect to the renal mRNA expression levels of the endothelial activation marker E-selectin (Table 1) . HFD feeding significantly upregulated E-selectin mRNA expression (2.41 ± 0.73, p < 0.001 vs. chow), and rosuvastatin was unable to prevent this increase (2.23 ± 0.85, n.s. vs. HFD). In contrast, rosiglitazone treatment considerably downregulated E-selectin mRNA expression (1.38 ± 0.54, p < 0.01 vs. HFD), with expression levels similar to those observed in chow-fed mice.
The expression of CD68 mRNA, a marker for macrophage infiltration, and VCAM-1 mRNA, a vascular endothelial activation marker, did not differ significantly between the experimental groups ( Table 1) .
Plasma markers of systemic inflammation. HuCRP levels were measured to monitor the overall systemic inflammatory state induced by HFD, and the effect of interventions with rosuvastatin and rosiglitazone thereupon. As reported previously, plasma huCRP levels were increased by HFD feeding and this induction was significantly quenched in animals treated with rosiglitazone or rosuvastatin 15 , as is also reflected by the significant reduction in huCRP exposure during HFD-feeding (Fig. 5a ). In contrast, only rosiglitazone markedly and significantly reduced the HFD-induced increase in plasma E-selectin levels at 42 weeks thus reflecting the renal mRNA data for E-selectin (Fig. 5b) .
Renal fibrosis and miR-21.
Renal fibrosis is a frequent underlying cause of decreased renal function. To gain insight into fibrosis development, kidneys were stained with Masson Trichrome and Picro-Sirius Red, and analyzed for collagen deposition. Figure 6a shows Masson's Trichrome staining with the corresponding collagen quantification (as quantified in Picro-Sirius Red-stained sections) in Fig. 6b . HFD induced the tubular interstitial collagen content (1.11 ± 0.44%) compared with the chow group (0.57 ± 0.31%; p < 0.01, Fig. 6b) . Notably, while collagen content after rosuvastatin treatment was comparable to that in the HFD group (1.27 ± 0.45%), rosiglitazone significantly prevented collagen deposition (0.74 ± 0.24%; p < 0.05 compared with HFD) with levels comparable to those in the chow group.
Since miR-21 has been shown to play a pathological role in many forms of fibrosis and since its increase is associated with microalbuminuria, inflammation and renal fibrosis 18, 19 , we examined renal miR-21 expression (Fig. 6c) . Renal miR-21 expression was enhanced in HFD compared with chow group (fold-change 1.66 ± 0.83 in HFD vs., 1.00 ± 0.42 in chow). Rosuvastatin treatment nearly doubled miR-21 expression (fold-change 3.16 ± 1.41 relative to chow; p < 0.01 compared with HFD) on top of HFD treatment. In contrast, rosiglitazone kept miR-21 levels low (fold-change 1.32 ± 1.02 relative to chow). To test whether miR-21 expression is connected to kidney pathology, we performed correlation analyses. Renal miR-21 expression correlated significantly with renal KIM-1 expression (Spearman r = 0.46, p = 0.02) and renal fibrosis (Spearman r = 0.52, p = 0.003) while no such correlations were found for plasma adiponectin levels or adiponectin exposure. Table 1 . Effects of rosiglitazone and rosuvastatin on renal mRNA expression. Fold-change relative to chow. Data are mean ± SD. Means in a row with superscripts that do not share a common letter differ significantly (p < 0.05).
Discussion
Obesity-related albuminuria is recognised as a first sign of declined kidney function. Among the factors suggested to connect obesity to kidney dysfunction are low-grade systemic inflammation, IR/T2D and adipokine dysregulation. In the current study we sought evidence for the role of these obesity-linked factors in the development of aspects of renal pathology, viz. albuminuria, inflammation and fibrosis. For this, we employed huCRPtg mice under conditions of HFD-induced obesity in conjunction with two pharmacological interventions, rosiglitazone and rosuvastatin, with established anti-inflammatory properties 15 , as exemplified by decreased huCRP levels. Our results demonstrate that anti-inflammatory rosiglitazone but not anti-inflammatory rosuvastatin prevented HFD-induced albuminuria and renal fibrosis, and inhibited expression of the renal inflammation marker, E-selectin. Rosiglitazone also prevented the HFD-enhanced mRNA expression of KIM-1, while rosuvastatin almost doubled KIM-1 mRNA levels. Notably, these beneficial effects of rosiglitazone were paralleled by absence of miR-21 induction, the expression of which was found to be correlated with kidney pathology (i.e. KIM-1 expression and kidney fibrosis).
In our study, we focused on human CRP levels as a marker for systemic inflammation. Recently, it has been reported that rosiglitazone treatment reduces plasma CRP levels in rats with streptozotocin-induced T2D 20 . Consistent with these findings, we observed that rosiglitazone treatment reduced human CRP levels in HFD-challenged huCRPtg mice indicating that rosiglitazone suppresses systemic inflammatory responses 15 . Rosiglitazone is a PPAR-γ agonist that belongs to the thiazolidinedione class of drugs. It has been reported that in patients with T2D, treatment with another thiazolidinedione (pioglitazone) along with insulin therapy decreased human CRP levels when compared to insulin treatment alone 21, 22 . In the current study, rosiglitazone reduced plasma insulin levels and hence reduced IR. In contrast, anti-inflammatory rosuvastatin treatment 15 failed to reduce circulating insulin levels, which is in line with a recent study showing that rosuvastatin failed to improve IR in patients on peritoneal dialysis 23 . Rosiglitazone treatment caused a significant increase in body weight in huCRPtg mice compared with HFD mice. More specifically, rosiglitazone-treated mice especially had increased subcutaneous fat mass compared with HFD mice. Consistent with these observations, treatment with PPAR-γ agonists has been shown to improve insulin sensitivity despite increasing body fat mass, in particular subcutaneously 21 . In contrast, an increase in visceral fat has been reported to be highly associated with IR and T2D 22, 23 . Here, we observed that rosiglitazone treatment decreased visceral fat mass. In contrast, in rosuvastatin-treated mice the mass and distribution of the fat depots were similar to those observed in untreated HFD-challenged mice.
We also observed that mice treated with rosiglitazone displayed markedly increased plasma levels of adiponectin, a protein predominantly secreted by adipocytes. It is well documented that adiponectin is a cardioprotective adipokine, due to its anti-inflammatory and insulin-sensitizing properties 24, 25 . An inverse relationship between adiponectin levels and CVD has been reported 15, 26 in patients with end-stage renal disease, and there is increasing evidence that adiponectin plays a protective role in T2D and IR. For example, adiponectin-deficient mice are prone to develop IR and vascular damage after HFD challenge 27 whereas treatment with adiponectin inhibits renal fibrosis and albuminuria in adiponectin knock-out mice 24 . Moreover, enhanced expression of adiponectin attenuates inflammation and diabetes development in db/db mice 28 . Since plasma levels of adiponectin and adiponectin exposure over time did not correlate with kidney disease severity (percentage of fibrosis and KIM-1 expression) in the present study it is unlikely that adiponectin plays a causal role under the experimental conditions applied herein. Obesity-related albuminuria is now being recognised not only as an indication of declined kidney function and a first sign of diabetic nephropathy 10 , but also increases the risk of CVD 29 . If left untreated, patients with albuminuria are more prone to CVD. Treatments that reduce albuminuria are therefore inherently renoprotective and would improve CVD outcomes 29 . We observed that mice on HFD developed mesangial expansion, lipid accumulation and albuminuria. Furthermore, KIM-1, a marker of kidney injury 30 , was upregulated in mice on HFD. Rosiglitazone treatment markedly diminished these HFD-induced renal effects and improved kidney function as evidenced by reduced urinary albumin/creatinine ratios and lowered KIM-1 expression. Moreover, rosiglitazone treatment strikingly reduced plasma E-selectin levels and, similarly, reduced renal E-selectin mRNA expression levels. Conversely, rosuvastatin treatment failed to exert any beneficial effects on markers of endothelial activation and inflammation in the kidney and did not improve albumin/creatinine ratios. In fact, the expression levels of some markers, including E-selectin and KIM-1 were increased in the kidneys of rosuvastatin-treated mice when compared with those of chow and HFD-challenged mice.
In a healthy individual, the kidney is able to reabsorb the majority of protein that enters the renal filtrate, with only traces being excreted in the urine. In the obese state there are two main sites involving two different processes that result in a loss of protein (mainly albumin) in the urine, viz. (i) structural changes to the glomerulus allowing more albumin to enter the filtrate and (ii) inability of the proximal tubules to endocytose the increased protein load (see ref. 9 and references therein). The development of albuminuria is a typical characteristic of renal damage (nephropathy ref. 31) . Previous studies have demonstrated that statins can inhibit tubular reabsorption of filtered albumin 32, 33 . Furthermore, this notion is supported by a recent study in hypertensive patients demonstrating that statin treatment was independently associated with the occurrence of microalbuminuria 34 . Exposure to raised levels of albumin in the renal tubule has been linked to increased proinflammatory and profibrotic changes in the tubulointerstitium 35 . Diabetic patients with end-stage kidney disease have a 5-year survival rate of merely 20% 36 . One of the major features of diabetic nephropathy is the presence of fibrosis. We observed increased collagen content in the HFD group. Notably, rosiglitazone, but not rosuvastatin treatment, prevented the increase in renal collagen deposition, suggesting a possible link between renal fibrosis and renal function. MiR-21 is the most substantial miRNA involved in many fibrotic diseases and its expression is enhanced after initiation of myocardial and pulmonary fibrosis 37, 38 . MiR-21 levels are also enhanced in human kidney fibrosis 18, 19 . Experimental support for a causative role of miR-21 is provided by miR21-silencing experiments. Silencing of miR-21 by anti-miR-21 oligonucleotide treatment in a murine model of Alport nephropathy reduced glomerulosclerosis, interstitial fibrosis, tubular injury, and inflammation 39 . Similarly, silencing miR-21 in diabetic kidneys of db/db mice ameliorated albuminuria, inflammation and renal fibrosis 40 . We observed highly enhanced miR-21 levels only after rosuvastatin treatment, whereas rosiglitazone prevented its expression and was comparable to the chow group. Notably, gene expression of pro-fibrotic genes like α-Sma and Col1α1 (results not shown) was unaffected suggesting that miR-21 could be an early marker of the initiating fibrosis in the kidneys.
In conclusion, our results demonstrate that rosiglitazone reduced HFD-induced insulin levels, suppressed the systemic inflammatory response and protected mice from the development of albuminuria. Despite its anti-inflammatory properties, rosuvastatin failed to improve IR and renal function. Strikingly, the beneficial effects of rosiglitazone were paralleled by lowered renal expression levels of miR-21; an increase of miR-21 is associated with microalbuminuria development, inflammation and renal fibrosis. In all, our findings suggest that adiponectin does not play a major role in the disease-attenuating effect of rosiglitazone and indicate that the option of quenching miR-21 activity merits follow-up. 
